BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 6732438)

  • 1. Increased risk for cancer of the breast due to previous medication.
    de Levin RW; Puig OR; Levin E
    Arch Geschwulstforsch; 1984; 54(2):153-8. PubMed ID: 6732438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rauwolfia use and breast cancer: a case-control study.
    Stanford JL; Martin EJ; Brinton LA; Hoover RN
    J Natl Cancer Inst; 1986 May; 76(5):817-22. PubMed ID: 3457968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cimetidine use and risk of prostate and breast cancer.
    Rossing MA; Scholes D; Cushing-Haugen KL; Voigt LF
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):319-23. PubMed ID: 10750671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
    Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cimetidine and other histamine2-receptor antagonist use in relation to risk of breast cancer.
    Coogan PF; Zhang Y; Palmer JR; Strom BL; Rosenberg L
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1012-5. PubMed ID: 15824181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Researchers can now investigate long-term effects of OCs on cancer.
    Rubin GL; Peterson HB
    Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer risk under hormone therapy].
    Lauritzen C
    Ther Umsch; 1994 Nov; 51(11):755-66. PubMed ID: 7839334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychotropic medication use and risk of epithelial ovarian cancer.
    Harlow BL; Cramer DW; Baron JA; Titus-Ernstoff L; Greenberg ER
    Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):697-702. PubMed ID: 9718222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration].
    Baumann M; Trincard M
    Encephale; 2002; 28(5 Pt 1):389-96. PubMed ID: 12386539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.
    Tworoger SS; Sluss P; Hankinson SE
    Cancer Res; 2006 Feb; 66(4):2476-82. PubMed ID: 16489055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X
    NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
    Harvey PW
    J Appl Toxicol; 2005; 25(3):179-83. PubMed ID: 15856525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Female sex hormones increase the risk of breast cancer].
    Vatten L
    Tidsskr Nor Laegeforen; 1998 Aug; 118(19):2969-74. PubMed ID: 9748837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral contraceptive use and the risk of cancer].
    Wingo PA
    Fertil Contracept Sex; 1989 Feb; 17(2):125-32. PubMed ID: 12281877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.